Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT04895709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04895709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 27, 2021
Completion date
August 31, 2031
Enrollment
1,109 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, cervical cancer, gastric/gastroesophageal junction adenocarcinoma, melanoma, microsatellite stable colorectal cancer, non-small-cell lung cancer, ovarian neoplasms, pancreatic adenocarcinoma, squamous cell carcinoma of head and neck, triple negative breast neoplasms, urothelial carcinoma